Healthcare / BiotechnologyTSXV
$0.11
-0.01 (-8.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-283933.00 · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
59.6x
↑EV/EBITDA
15.8x
↑ROE
2.6%
↑Gross Margin
52.9%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+59.1%
FCF CAGR
—
FCF margin
-11.8%
FCF / Net income
-5.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.5M · net income $94375.0 · FCF $-533871.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.5M | $4.5M | $2.2M | $1.2M | $1.1M |
| Net Income | $94375.00 | $94375.00 | $224735.00 | $-157582.00 | $-136511.00 |
| EBITDA | $264466.00 | $264466.00 | $286357.00 | $-78761.00 | $-17330.00 |
| EPS | 0.00 | 0.00 | 0.01 | -0.00 | -0.00 |
| Gross Margin | 52.9% | 52.9% | 50.6% | 40.7% | 69.2% |
| Operating Margin | 0.5% | 0.5% | 2.2% | -32.1% | -12.5% |
| Net Margin | 2.1% | 2.1% | 10.2% | -13.3% | -12.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | — | — | 0.04 |
| Current Ratio | 3.28 | 3.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-533871.00 | $-533871.00 | $-283933.00 | $-270956.00 | $136868.00 |
| Returns | |||||
| ROE | 2.6% | 2.6% | 8.8% | -16.9% | -12.9% |
| Valuation | |||||
| P/E | 59.62 | 59.62 | 32.82 | — | — |
| EV/EBITDA | 15.76 | 15.76 | 23.23 | — | — |
| P/B | 1.56 | 1.56 | 2.88 | 4.20 | 5.22 |
| Growth & Yield | |||||
| Revenue Growth | 106.6% | 106.6% | 85.6% | 5.0% | — |
| EPS Growth | -66.4% | -66.4% | 235.4% | -15.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
74.2%
EPS terminal req.
$0.01
Spread vs growth
-140.6%
5Y implied EPS CAGR
45.0%
EPS terminal req.
$0.01
Spread vs growth
-111.3%
10Y implied EPS CAGR
26.3%
EPS terminal req.
$0.02
Spread vs growth
-92.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-54.2%
Start / end P/E
43.8x → 59.6x
EPS bridge
0.01 → 0.00
Residual
-24.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.